Literature DB >> 21845796

Buprenorphine/naloxone versus methadone in opioid dependence: a longitudinal survey.

F Curcio1, T Franco, M Topa, C Baldassarre.   

Abstract

BACKGROUND AND OBJECTIVES: Buprenorphine and methadone are widely used for the treatment of opioid dependence, but their diversion and/or misuse are frequent. In principle, buprenorphine/naloxone combination therapy should be associated with a lower frequency of drug abuse/misuse than methadone. This study assessed the efficacy of the substitution of buprenorphine treatment with the buprenorphine/naloxone combination in opioid-dependent patients.
MATERIAL AND METHODS: 3812 drug-addicted outpatients selected from 10 Italian Public Services for Addiction (Ser.T.) centres in Naples (Italy) were enrolled: 3105 (81.5%) were treated with methadone and 707 (18.5%) with buprenorphine. The buprenorphine treatment was switched to buprenorphine/naloxone (4:1), and the patients were followed for about 1 year. The number of subjects still on treatment after 1 year, their status according to social, educational and toxicologic (assessed by a urine toxicology test) parameters were assessed.
RESULTS: 1 year after the therapy switch, the number of patients still on treatment was similarly reduced with methadone (2883; -7.5%) and buprenorphine/naloxone (632; -10.6%; p=0.369). However, in patients treated with buprenorphine/naloxone, a significant improvement was reported in social life status (63% versus 39% of the buprenorphine/naloxone and methadone treated subjects, respectively, were married/cohabiting p<0.001), in the educational level (43% of buprenorphine/naloxone treated versus 32% of the methadone treated subjects obtained at least a high school certificate, p<0.001) and in the toxicological conditions (53% of buprenorphine/naloxone treated subject versus 30% of methadone treated individuals had opioid- and cocaine- negative urine tests, p<0.001). DISCUSSION: These preliminary data suggest that buprenorphine/naloxone treatment of opioid dependence reduces the percentage of treated subjects similarly to methadone, and is associated with an improvement in social life, educational and toxicological conditions, compared with methadone treatment. However, we cannot exclude a selection bias, i.e. patients who were more likely to stabilize their opiate dependence switched to buprenorphine/naloxone.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21845796

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

Review 1.  Retention in medication-assisted treatment for opiate dependence: A systematic review.

Authors:  Christine Timko; Nicole R Schultz; Michael A Cucciare; Lisa Vittorio; Christina Garrison-Diehn
Journal:  J Addict Dis       Date:  2015-10-14

Review 2.  Long term outcomes of pharmacological treatments for opioid dependence: does methadone still lead the pack?

Authors:  Maria Paz Garcia-Portilla; Maria Teresa Bobes-Bascaran; Maria Teresa Bascaran; Pilar Alejandra Saiz; Julio Bobes
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

3.  A randomized clinical trial of buprenorphine for prisoners: Findings at 12-months post-release.

Authors:  Michael S Gordon; Timothy W Kinlock; Robert P Schwartz; Kevin E O'Grady; Terrence T Fitzgerald; Frank J Vocci
Journal:  Drug Alcohol Depend       Date:  2017-01-11       Impact factor: 4.492

4.  Risk factors for stimulant use among homeless and unstably housed adult women.

Authors:  Elise D Riley; Martha Shumway; Kelly R Knight; David Guzman; Jennifer Cohen; Sheri D Weiser
Journal:  Drug Alcohol Depend       Date:  2015-05-27       Impact factor: 4.492

5.  The relative risk of fatal poisoning by methadone or buprenorphine within the wider population of England and Wales.

Authors:  Dave Marteau; Rebecca McDonald; Kamlesh Patel
Journal:  BMJ Open       Date:  2015-05-29       Impact factor: 2.692

6.  The effectiveness of opioid substitution treatments for patients with opioid dependence: a systematic review and multiple treatment comparison protocol.

Authors:  Brittany Burns Dennis; Leen Naji; Monica Bawor; Ashley Bonner; Michael Varenbut; Jeff Daiter; Carolyn Plater; Guillaume Pare; David C Marsh; Andrew Worster; Dipika Desai; Zainab Samaan; Lehana Thabane
Journal:  Syst Rev       Date:  2014-09-19

7.  Sexual Dysfunction in Heroin Dependents: A Comparison between Methadone and Buprenorphine Maintenance Treatment.

Authors:  Anne Yee; Mahmoud Danaee; Huai Seng Loh; Ahmad Hatim Sulaiman; Chong Guan Ng
Journal:  PLoS One       Date:  2016-01-28       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.